THX Pharma and Biocodex entered into a strategic license agreement for the further development of two drug candidates: Batten-1 and TX01.[1][2] The contract covers three rare diseases with high untapped medical need: juvenile Batten disease (CLN3), Gaucher disease and Niemann-Pick type C disease.[1][2] Biocodex has obtained an exclusive worldwide license to develop and commercialize Batten-1, which is in preparation for Phase 3 (planned to start in 2026) with a goal of international launch in 2030.[1][2] For TX01, a new oral formulation of an already approved substance, Biocodex obtained an exclusive license for the USA and Canada.[1][2] The deal is valued at up to €173 million, including an upfront payment of €12 million, up to €161 million in development and commercialization milestones, and double-digit royalties on net sales.[2][3] THX Pharma will lead clinical development, including Phase 3 for Batten-1 with scientific and financial support from Biocodex, which will provide marketing authorizations and commercialization.[1][2] Batten-1 is expected to be the first approved drug for juvenile Batten disease, which leads to loss of vision, cognitive and motor function, and death in early adulthood.[1]